Lexeo Therapeutics, Inc. (LXEO)Healthcare | Biotechnology | New York, United States | NasdaqGM
4.86 USD
-0.13
(-2.605%) ⇩
(Aug. 28, 2026, 4 p.m.
EDT)
After hours: 4.77 -0.09 (-0.090%) ⇩ (Aug. 28, 2026, 7:36 p.m. EDT) |
Hot Take ↕ | Aug. 22, 2026, 5:16 a.m. EDT
The long-term investment case is severely compromised by a brutal 59.77% cumulative decline over the last year, driven by a single catastrophic -59.77% annual drop. This is not a temporary correction; it is a structural implosion where the market has priced out the business entirely. Fundamentals confirm this distress: the company is burning cash aggressively (-$88M operating cash flow), posting negative returns on equity (-46%), and trading at a negative forward P/E. Despite a 'strong buy' analyst recommendation and a lofty $30 price target, these are likely speculative hopes for a turnaround that the balance sheet cannot currently support. The short-term outlook remains fragile; while the stock recently bounced off lows, the heavy put option positioning suggests traders are still bracing for further pain. With no dividend to provide income and a high short ratio indicating skepticism, this remains a high-risk speculative vehicle rather than a viable investment. |
| Model | MAE |
|---|---|
| MSTL ✓ | 0.102840 |
| AutoTheta | 0.108083 |
| AutoETS | 0.109769 |
| AutoARIMA | 0.110432 |
Forecast horizon: 45 days | Selected: MSTL
| Forecast Reliability | |
|---|---|
| Score | 36% |
| H-stat | 1.05 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.757 |
| Excess Kurtosis | -0.54 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 2.898 |
| Market Cap | 398,744,800 |
| Forward P/E | -3.55 |
| Beta | 1.47 |
| Website | https://www.lexeotx.com |
As of Aug. 22, 2026, 5:16 a.m. EDT: Speculators are heavily positioned for downside protection, with massive open interest in out-of-the-money puts (strikes 6.0 and 7.0) relative to calls. While there is some new call volume at lower strikes (3.0, 4.0), the overwhelming weight of capital is betting on further declines, creating a distinct 'bearish hedge' bias rather than a bullish breakout expectation.
| Attribute | Value |
|---|---|
| 52 Week Change | 0.014613748 |
| Address1 | 345 Park Avenue South |
| Address2 | 6th Floor |
| All Time High | 22.33 |
| All Time Low | 1.45 |
| Ask | 5.76 |
| Ask Size | 2 |
| Audit Risk | 7 |
| Average Analyst Rating | 1.2 - Strong Buy |
| Average Daily Volume10 Day | 804,390 |
| Average Daily Volume3 Month | 942,700 |
| Average Volume | 942,700 |
| Average Volume10Days | 804,390 |
| Beta | 1.465 |
| Bid | 3.32 |
| Bid Size | 2 |
| Board Risk | 5 |
| Book Value | 3.125 |
| City | New York |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 9 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 4.86 |
| Current Ratio | 13.887 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,786,665,600 |
| Day High | 4.96 |
| Day Low | 4.73 |
| Debt To Equity | 2.898 |
| Display Name | Lexeo Therapeutics |
| Earnings Timestamp | 1,786,537,800 |
| Earnings Timestamp End | 1,793,795,400 |
| Earnings Timestamp Start | 1,793,795,400 |
| Ebitda | -94,504,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -2.051 |
| Enterprise Value | 193,834,208 |
| Eps Current Year | -1.19857 |
| Eps Forward | -1.36857 |
| Eps Trailing Twelve Months | -0.86 |
| Esg Populated | 0 |
| Exchange | NGM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 4.7472 |
| Fifty Day Average Change | 0.11280012 |
| Fifty Day Average Change Percent | 0.023761401 |
| Fifty Two Week Change Percent | 1.4613748 |
| Fifty Two Week High | 10.99 |
| Fifty Two Week High Change | -6.1299996 |
| Fifty Two Week High Change Percent | -0.5577798 |
| Fifty Two Week Low | 3.99 |
| Fifty Two Week Low Change | 0.8700001 |
| Fifty Two Week Low Change Percent | 0.21804515 |
| Fifty Two Week Range | 3.99 - 10.99 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,699,018,200,000 |
| Float Shares | 51,225,651 |
| Forward Eps | -1.36857 |
| Forward P E | -3.551152 |
| Free Cashflow | -58,791,752 |
| Full Exchange Name | NasdaqGM |
| Full Time Employees | 63 |
| Fullday Change | -0.13 |
| Fullday Change Percent | -2.6052 |
| Fullday Price | 4.77 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,785,542,400 |
| Gross Margins | 0.0 |
| Gross Profits | -66,635,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.00636 |
| Held Percent Institutions | 1.14399 |
| Implied Shares Outstanding | 82,046,255 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ipo Expected Date | 2,023-11-03 |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Lexeo Therapeutics, Inc., a clinical stage genetic medicine company, focuses on hereditary and acquired diseases with high unmet need in the United States. Its product pipeline comprises LX2006, an AAVrh10-based gene therapy candidate, which is in phase 1/2 clinical trial to treat friedreich ataxia cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate, which is in phase 1/2 to deliver a functional plakophilin-2 (PKP2) gene to cardiac muscle for the treatment of PKP2-ACM; and LX2021, a gene therapy candidate, which is in preclinical trial to deliver the coding sequence for the functional connexin 43, or Cx43, protein for a group of inherited cardiac muscle disorders associated with a high risk of sudden death, including arrhythmogenic cardiomyopathy (ACM) and certain forms of dilated cardiomyopathy. The company is also developing LX2022, a gene therapy candidate, which is in preclinical trial to deliver a functional TNNI3 gene to myocardial cells to treat a distinct form of hypertrophic cardiomyopathy. In addition, it is developing LX1001, LX1020, and LX1021, an AAVrh10-based gene therapy candidate, which has completed phase 1/2 clinical trial for the treatment of APOE4-associated Alzheimer's disease. The company has a license agreement with Cornell University to conduct the Phase 1/2 clinical trial of LX1001, as well as support the development of the LX1004 program; a research collaboration agreement with Cornell University to conduct preclinical research to develop the licensed technology; and third license agreement which obtained certain rights for FA cardiomyopathy, including rights to current and future clinical data from an ongoing Cornell University investigator-initiated Phase 1A trial of a gene therapy candidate. The company was founded in 2017 and is headquartered in New York, New York. |
| Long Name | Lexeo Therapeutics, Inc. |
| Market | us_market |
| Market Cap | 398,744,800 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_625814286 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -87,265,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 409,410,812 |
| Number Of Analyst Opinions | 10 |
| Open | 4.945 |
| Operating Cashflow | -88,367,000 |
| Operating Margins | 0.0 |
| Overall Risk | 7 |
| Payout Ratio | 0.0 |
| Phone | 212 547 9879 |
| Post Market Change | -0.09000015 |
| Post Market Change Percent | -1.8518549 |
| Post Market Price | 4.77 |
| Post Market Time | 1,787,960,193 |
| Previous Close | 4.99 |
| Price Eps Current Year | -4.054832 |
| Price Hint | 4 |
| Price To Book | 1.5552001 |
| Profit Margins | 0.0 |
| Quick Ratio | 13.574 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.22222 |
| Region | US |
| Regular Market Change | -0.13 |
| Regular Market Change Percent | -2.6052 |
| Regular Market Day High | 4.96 |
| Regular Market Day Low | 4.73 |
| Regular Market Day Range | 4.73 - 4.96 |
| Regular Market Open | 4.945 |
| Regular Market Previous Close | 4.99 |
| Regular Market Price | 4.86 |
| Regular Market Time | 1,787,947,201 |
| Regular Market Volume | 663,603 |
| Return On Assets | -0.27587998 |
| Return On Equity | -0.46756 |
| Sand P52 Week Change | 0.20204377 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 8 |
| Shares Outstanding | 82,046,255 |
| Shares Percent Shares Out | 0.2496 |
| Shares Short | 20,477,587 |
| Shares Short Previous Month Date | 1,784,073,600 |
| Shares Short Prior Month | 16,348,536 |
| Short Name | Lexeo Therapeutics, Inc. |
| Short Percent Of Float | 0.2912 |
| Short Ratio | 20.34 |
| Source Interval | 15 |
| State | NY |
| Symbol | LXEO |
| Target High Price | 30.0 |
| Target Low Price | 9.0 |
| Target Mean Price | 20.3 |
| Target Median Price | 20.0 |
| Total Cash | 211,703,008 |
| Total Cash Per Share | 2.58 |
| Total Debt | 6,811,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -0.86 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 6.504525 |
| Two Hundred Day Average Change | -1.644525 |
| Two Hundred Day Average Change Percent | -0.25282785 |
| Type Disp | Equity |
| Volume | 663,603 |
| Website | https://www.lexeotx.com |
| Zip | 10,010 |